Literature DB >> 7786002

Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis.

M de Górgolas1, P Avilés, C Verdejo, M L Fernández Guerrero.   

Abstract

Using two strains of Staphylococcus aureus, one susceptible and one heterogeneously resistant to methicillin, for which MICs and MBCs of trimethoprim-sulfamethoxazole (TMP-SMX) were 0.06 and 0.06 micrograms/ml and 0.06 and 0.25 microgram/ml, respectively (concentrations are those of TMP), we studied the efficacies of TMP-SMX and cloxacillin, teicoplanin, and vancomycin for treatment of experimental staphylococcal endocarditis. Rabbits were treated with dosages of TMP-SMX selected to achieve concentrations in serum equivalent to that obtained in humans treated for Pneumocystis carinii pneumonia. The overall mortality rate of rabbits treated with TMP-SMX was 84% at day 3, not different from that of the control groups (P > 0.1). No sterile vegetations were observed to be present in control groups or in animals treated with TMP-SMX. However, 26, 60, and 75% of rabbits treated with teicoplanin, cloxacillin, and vancomycin, respectively, showed sterile vegetations. For methicillin-susceptible S. aureus (MSSA), the mean vegetation counts were not significantly different between the control group and the group treated with TMP-SMX (P > 0.1). For methicillin-resistant S. aureus (MRSA), treatment with TMP-SMX was more effective than no therapy, decreasing the number of organisms in vegetations (P < 0.01). For both strains, therapy with cloxacillin and therapy with teicoplanin or vancomycin were significantly more effective than therapy with TMP-SMX. Despite high concentrations of teicoplanin in serum which exceeded MBCs for staphylococci more than 50 times at the peak and 10 times at the trough, therapy with cloxacillin or vancomycin was superior to therapy with teicoplanin against both MSSA and MRSA. These data do not support the use of TMP-SMX in treatment of endocarditis and other severe staphylococcal infections with high bacterial counts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786002      PMCID: PMC162660          DOI: 10.1128/AAC.39.4.953

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Experimental endocarditis.

Authors:  L R Freedman; S Arnold; J Valone
Journal:  Ann N Y Acad Sci       Date:  1974-07-31       Impact factor: 5.691

2.  Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia.

Authors:  E Bengtsson; M Svanbom; G Tunevall
Journal:  Scand J Infect Dis       Date:  1974

3.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

4.  Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis.

Authors:  M A Tamer; J D Bray
Journal:  Clin Pediatr (Phila)       Date:  1982-02       Impact factor: 1.168

5.  In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.

Authors:  T Lawrence; C Rotstein; T R Beam; E A Gorzynski; D Amsterdam
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

7.  Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia.

Authors:  D J Winston; W K Lau; R P Gale; L S Young
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

9.  Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole.

Authors:  W E Grose; G P Bodey; T L Loo
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more
  14 in total

1.  Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.

Authors:  José M Entenza; Andreas Haldimann; Marlyse Giddey; Sergio Lociuro; Stephen Hawser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

2.  Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres.

Authors:  David B Huang; Ian Morrissey; Timothy Murphy; Stephen Hawser; Mark H Wilcox
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-08       Impact factor: 3.267

3.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

4.  Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin resistant Staphylococcus aureus infections.

Authors:  C R Kumana; T Y Ching; Y Kong; E C Ma; M Kou; R A Lee; V C Cheng; S S Chiu; W H Seto
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

5.  How best to deal with endocarditis.

Authors:  Andrew Mark Morris
Journal:  Curr Infect Dis Rep       Date:  2006-01       Impact factor: 3.725

Review 6.  Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 7.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis.

Authors:  G Euba; O Murillo; N Fernández-Sabé; J Mascaró; J Cabo; A Pérez; F Tubau; R Verdaguer; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

10.  Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.

Authors:  Kristina Nadrah; Franc Strle
Journal:  Chemother Res Pract       Date:  2011-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.